Cardiovascular Revascularization Medicine
Volume 10, Issue 1 , Pages 5-11 , January 2009

Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus

Received 16 May 2008 ,Revised 19 June 2008 ,Accepted 23 June 2008.

References 

  1. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents (part I & part II). Circulation 2003;107:2274-2279, 2383-2389.
  2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  3. Hill RA, Dundar Y, Bakhai A, Dickson R, Wally T. Drug-eluting stents: an early systemic review to inform policy. Eur Heart J. 2004;25:902–919
  4. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583–591
  5. Katritsis DG, Karvouni E, loannidis JP. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol. 2005;95:640–643
  6. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784–2814
  7. Hoffmann R, Mintz GS. Coronary in-stent restenosis—predictors, treatment and prevention restenosis. Eur Heart J. 2000;21:1739–1749
  8. Takagi T, Yamamuro A, Tomita K, Yamabe K, Katayama M, Morioka S, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol. 2002;89:318–322
  9. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005;112:2792–2798
  10. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in type 2 diabetes. Diabetes Care. 2006;29:101–106
  11. Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention. Diabetes Care. 2007;30:384–388
  12. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  13. Nishio K, Fukui T, Tsunoda F, Kawamura K, Itoh S, Konno N, et al. Insulin resistance as an independent risk factor for restenosis after coronary stenting. Intern J Cardiol. 2005;103:128–134
  14. Alberti KGMM, Zimmet P for the WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus-provisional report of a WHO consultation. Diabetic Med. 1998;15:539–553
  15. Anon . Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21:1502–1513
  16. Anon . Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  17. Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Ryden L, et al. Diabetes, insulin resistance, and metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care. 2003;26:2770–2776
  18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–419
  19. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1978;18:499–502
  20. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44:1373–1385
  21. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1466–1467
  22. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093–1104
  23. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866–1873
  24. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol. 1999;34:1498–1506
  25. Mudra H, di Marco C, de Jaegere P, Figulla HR, Macaya C, Zahn R, et al. A randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation. 2001;104:1343–1349
  26. Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, Lopez-Minguez JR, Moreu J, Calvo I, et al. Direct coronary stenting versus stenting with balloon predilation: the DISCO trial: Direct Stenting of COronary Arteries. Eur Heart J. 2002;23:633–640
  27. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care. 2004;27:990–994
  28. Scheen AJ, Warzée F. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care. 2004;27:1840–1841
  29. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  30. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  31. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2006;297:159–168
  32. Miyazaki Y, Mahankali A, Matsuda M. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710–719
  33. Goetze S, Xi XP, Kawano H. PPAR gamma-ligands inhibits migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovascular Pharmacol. 1999;33:798–806
  34. Igarashi M, Hirata A, Yamaguchi H. Characterization of an inhibitory effect of pioglitazone in balloon-injured vascular smooth muscle cell growth. Metabolism. 2001;50:955–962
  35. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension. 2002;40:687–693
  36. Nishio K, Shigemitsu M, Kusuyama T, Fukui T, Kawamura K, Itoh S, et al. Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc Revasc Med. 2006;7:54–60
  37. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865–873
  38. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with Type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol. 2007;49:1772–1780
  39. Schömig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy back to future?. Circulation. 2005;112:2759–2761
  40. Hoffmann R, Mintz GS, Mehran R. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol. 1998;31:43–49

☆ Clinical trials.gov: Protocol Registration System; NCT 00482183.

PII: S1553-8389(08)00244-3

doi: 10.1016/j.carrev.2008.06.004

Cardiovascular Revascularization Medicine
Volume 10, Issue 1 , Pages 5-11 , January 2009

Article Tools

* Image Usage & Resolution